Quantcast

Latest Monoclonal antibodies Stories

2014-06-03 12:39:19

Leveraging Nurse Support Could Boost Engagement with Rheumatoid Arthritis Brands, According to Findings in New Manhattan Research Analysis from Decision Resources Group BURLINGTON, Mass., June 3, 2014 /PRNewswire/ -- Manhattan Research's new Digital Competitive Landscape analysis finds that many rheumatoid arthritis (RA) brands are overlooking valuable ways to reach patients and physicians through digital channels and support their evolving needs. Each opportunity represents a risk in a...

2014-06-01 23:01:09

LifeScienceIndustryResearch.com adds Latest Report on “Frontier Pharma: Psoriasis – Identifying and Commercializing First-in-Class Innovation” to its store. Dallas, TX (PRWEB) June 01, 2014 Psoriasis is a chronic, inflammatory disease triggered by deregulated Thymus-derived (T) cells, resulting inflammation and benign hyperplasia of keratinocytes within the skin. Manifestations of affected skin are red, thickened plaques with an overlying silver-white scale, which significantly...

2014-05-29 04:22:19

BREDA, The Netherlands and GHENT, Belgium, May 29, 2014 /PRNewswire/ -- arGEN-X will present full results from the dose-escalation part of a Phase 1 study of ARGX-110, a novel anti-CD70 antibody, in patients with advanced hematological and solid tumors at the 50th annual meeting of the American Society of Clinical Oncology (ASCO; 30 May-3 June, 2014, Chicago, IL, USA). arGEN-X reported in December 2013 that this study met its translational development goals: all...

2014-05-28 08:31:16

MONROVIA, Calif., May 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the first subject has been dosed in a Phase 1a clinical trial of XmAb®7195. XmAb7195 is a monoclonal antibody engineered to suppress IgE via three distinct mechanisms of action as a potential treatment for asthma and...

2014-05-27 04:21:43

Protection Data Presented at the 17th Annual Meeting of the American Society of Gene & Cell Therapy BLUE BELL, Pa., May 27, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge. In this preclinical study, a prototype DNA plasmid construct encoding for a monoclonal antibody for CHIKV envelope protein was...

2014-05-26 13:21:07

University of Texas M. D. Anderson Cancer Center Peptide antibodies hit immune-response-stifling MDSCs without harming other vital cells Scientists have found a way to target elusive cells that suppress immune response, depleting them with peptides that spare other important cells and shrink tumors in preclinical experiments, according to a paper published online by Nature Medicine. "We've known about these cells blocking immune response for a decade, but haven't been able to shut...

2014-05-23 04:20:53

LONDON, May 23, 2014 /PRNewswire/ -- New Company Created to be a Leading Provider of Technologies and Services to Enable Better Biopharmaceuticals - PolyTherics and Antitope to continue to trade as wholly owned subsidiaries of Abzena - New brand highlights depth and range of offering to the global biopharmaceutical industry - Abzena to establish headquarters in Cambridge, UK PolyTherics Limited ("PolyTherics"), a...

2014-05-22 10:49:08

CSH Scientists at Cold Spring Harbor Laboratory (CSHL) today report a discovery that they hope will lead to the development of a powerful new way of treating an aggressive form of breast cancer. The breast cancer subtype in question is commonly called “HER2-positive”; it’s a subset of the disease affecting about one patient in four, in which tumor cells overexpress a signaling protein called HER2.  The blockbuster drug Herceptin is a first-line treatment for many women with...

2014-05-22 08:29:44

MONROVIA, Calif., May 22, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the Jefferies 2014 Global Healthcare Conference on Thursday, June 5, 2014 at 8:00 a.m. EDT in New York City, NY. A live audio webcast of the...

2014-05-20 23:02:55

New comprehensive research report “Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies” elaborated by GBI Research is now available at MarketPublishers.com. According to the study, the global ovarian cancer therapeutics market is anticipated to post a 3.4% CAGR through 2020. London, UK (PRWEB) May 20, 2014 At present, the overall ovarian cancer therapeutics market is led by the use of...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related